Proton beam therapy for intrathoracic tumors—current status and future perspectives

被引：0
作者：
Troost E.G.C. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] OncoRay – Nationales Zentrum für Strahlenforschung in der Onkologie, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden
[2] Institut für Radioonkologie – OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden
[3] Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden
[4] Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort Dresden, und Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
[5] Nationales Zentrum für Tumorerkrankungen (NCT), Partnerstandort Dresden: Deutsches Krebsforschungszentrum (DKFZ)
[6] Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, und Helmholtz-Gemeinschaft/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden
来源：
best practice onkologie | 2020年 / 15卷 / 12期
关键词：
Esophageal carcinomas; Non-small cell lung cancer; Proton beam therapy; Radiotherapy; Small cell lung cancer;
D O I：
10.1007/s11654-020-00262-z
中图分类号：
学科分类号：
摘要：
Conventional external beam radiation therapy with high-energy photons is one of the pillars of treatment for patients with intrathoracic tumors. Due to technical advances, e.g., highly conformal, image-guided irradiation techniques, it has been possible to increase local tumor control while simultaneously reducing treatment-associated side effects. In recent years, proton beam therapy has become an alternative at an increasing number of national and international sites. At present, only four German sites offer protons for treatment of tumors outside of the eye, but the demand is increasing continually. Due to the physical characteristics of protons, i.e., the steep dose fall-off beyond the point of maximum dose deposition that is normally located in the tumor, normal tissue and organs at risk beyond the tumor can be spared. This review highlights the value of proton beam therapy for intrathoracic tumors. © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
引用
收藏
页码：534 / 540
页数：6
相关论文
共 36 条
  • [1] Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., Wagner H., Aisner S., Johnson D.H., Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide, N Engl J Med, 340, 4, pp. 265-271, (1999)
  • [2] Faivre-Finn C., Falk S., Blackhall F., The CONVERT trial: interpretation, journey and lessons learnt, Clin Oncol (R Coll Radiol), 29, 12, pp. 811-813, (2017)
  • [3] van Baardwijk A., Tome W.A., van Elmpt W., Bentzen S.M., Reymen B., Wanders R., Houben R., Ollers M., Lambin P., De Ruysscher D., Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review, Radiother Oncol, 105, 2, pp. 145-149, (2012)
  • [4] Palma D., Visser O., Lagerwaard F.J., Belderbos J., Slotman B., Senan S., Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery, Radiother Oncol, 101, 2, pp. 240-244, (2011)
  • [5] Palma D., Visser O., Lagerwaard F.J., Belderbos J., Slotman B.J., Senan S., Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis, J Clin Oncol, 28, 35, pp. 5153-5159, (2010)
  • [6] Palma D.A., Tyldesley S., Sheehan F., Mohamed I.G., Smith S., Wai E., Murray N., Senan S., Stage I non-small cell lung cancer (NSCLC) in patients aged 75 years and older: does age determine survival after radical treatment?, J Thorac Oncol, 5, 6, pp. 818-824, (2010)
  • [7] Wink K.C.J., Roelofs E., Simone C.B., Dechambre D., Santiago A., van der Stoep J., Dries W., Smits J., Avery S., Ammazzalorso F., Jansen N., Jelen U., Solberg T., De Ruysscher D., Troost E.G.C., Photons, protons or carbon ions for stage I non-small cell lung cancer—results of the multicentric ROCOCO in silico study, Radiother Oncol, 128, 1, pp. 139-146, (2018)
  • [8] Auperin A., Le Pechoux C., Rolland E., Curran W.J., Furuse K., Fournel P., Belderbos J., Clamon G., Ulutin H.C., Paulus R., Yamanaka T., Bozonnat M.C., Uitterhoeve A., Wang X., Stewart L., Arriagada R., Burdett S., Pignon J.P., Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer, J Clin Oncol, 28, 13, pp. 2181-2190, (2010)
  • [9] Bradley J.D., Paulus R., Komaki R., Masters G., Blumenschein G., Schild S., Bogart J., Hu C., Forster K., Magliocco A., Kavadi V., Garces Y.I., Narayan S., Iyengar P., Robinson C., Wynn R.B., Koprowski C., Meng J., Beitler J., Gaur R., Curran W., Choy H., Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two
  • [10] Bradley J.D., Hu C., Komaki R.R., Masters G.A., Blumenschein G.R., Schild S.E., Bogart J.A., Forster K.M., Magliocco A.M., Kavadi V.S., Narayan S., Iyengar P., Robinson C.G., Wynn R.B., Koprowski C.D., Olson M.R., Meng J., Paulus R., Curran W.J., Choy H., Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer, J Clin Oncol, 38, 7, pp. 706-714, (2020)
1234